| Literature DB >> 36196423 |
Terman Frometa-Castillo1, Anil Pyakuryal2, Ganesh Narayanasamy3, Asghar Mesbahi4, Amadeo Wals-Zurita5.
Abstract
Background: The NTCP methodology evaluating side-effects (S-Es) was initially used in radiotherapy (RT), and later was extended to brachytherapy (BT). The NTCP0 methodology has been recently introduced in RT. Given the advantages, this methodology could replace NTCP. Materials and methods: Revisions of studies related to use of NTCP in the evaluations of S-Es in BT. Development of the first versions of two Matlab applications of the NTCP0 methodology. These applications have three options. Two of them employ the well-known aspects of a phenomenological model, or the probabilistic relationship between NTCP0 and total NTCP (TNTCP) that is the sum(NTCP(x i )) i: i th complication i:1..nc: Number of complications; where NTCP0 = 100% - TNTCP; and the third option assumes a NTCP(xi) discrete probabilistic distribution generated by the binomial distribution, where one of its parameters is automatically obtained from a databased of the Disease locations Vs. Late complications.Entities:
Keywords: LKB NTCP model; NTCP; binomial distribution; brachytherapy; side-effect
Year: 2022 PMID: 36196423 PMCID: PMC9521694 DOI: 10.5603/RPOR.a2022.0063
Source DB: PubMed Journal: Rep Pract Oncol Radiother ISSN: 1507-1367
Figure 1Diagram of procedures for determining NTCP0 in a fractional BT treatment. Dpres — prescribed dose; NTCPi — NTCP for the ith complication; i — 1... nc, nc number of complications; DPD — discrete probabilistic distribution; SMp — statistical model project
Figure 2Hypothetical example of a NTCP(xi) discrete probabilistic distribution for describing or assuming the probabilities of late complications associated with a BT treatment for prostate cancer. D — prescribed dose; NTC0 — no complication; NTC1 — leakage of urine; NTC2 — cancer of the bladder; NTC3 — cancer of the lower bowel; NTC4 — erection problems (impotence). The NTCP0 = NTCP0 = 24% is represented by a x; and its value increases if D or R0 decreases, and vice versa, as is shown by the four arrows on the right side of the y-axis
Figure 3An example of the third option of the NTCP0cal/NTCP0CalDr application for an assumed NTCP distribution generated by the BD expression: BD(x;0.4,6) for a head & neck disease location
Late complications of the BT treatments for their correspondent disease location
| Late complications | Disease location | ||||
|---|---|---|---|---|---|
| Head and Neck | Breast | Chest | Abdomen | Pelvis | |
| Radiation (Rad.) brain | [ | ||||
| Rad. induced optic neuropathy | [ | ||||
| Myelopathy | [ | [ | [ | [ | [ |
| Sensorineural hearing loss | [ | ||||
| Xerostomia | [ | ||||
| Rad. larynx and pharynx complications | [ | ||||
| Rad. lung | [ | [ | |||
| Rad. heart | [ | [ | |||
| Rad. esophagus | [ | [ | [ | ||
| Liver dysfunction | [ | [ | [ | ||
| Rad. stomach and small bowel | [ | [ | |||
| Rad. kidney | [ | [ | |||
| Genitourinary | [ | [ | |||
| Rad. rectal | [ | [ | |||
| Rad. penile bulb | [ | [ | |||
Figure 4Illustrations of a generic example of a BT treatment with a constant number of fractions (n) dose per fractions, and (A): for dose per fraction d1; (B): d2; (C): d3; (D): d4; (E): d5 and (F): d6; where < d2 < d3 < d4 < d5 and < d6. The treatment has associated five late complications (C1, C2, C3, C4 and Others). We graphically and numerically show the independent variations of each late complications, and NTCP0